ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals received a credit rating reaffirmation from CARE Ratings for its existing bank facilities. The company maintains its stable outlook and financial profile.
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals has issued a notice for its 45th Annual General Meeting to be held on September 21, 2026. The meeting will address financial statements, dividends, and directorship appointments.
Emcure Pharmaceuticals has filed its Annual Report for the financial year 2025-26 and the notice for its 45th Annual General Meeting.
Emcure Pharmaceuticals has allotted 19,100 equity shares to employees following the exercise of vested ESOPs. The paid-up capital of the company has increased accordingly.
Emcure Pharmaceuticals received an Establishment Inspection Report (EIR) from the USFDA, classifying its Sanand facility inspection as 'Voluntary Action Indicated' and effectively closing the inspection.